| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5814639 | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(8 years ago) | |
| US5914331 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(6 years ago) | |
| US5922695 | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(6 years ago) | |
| US5977089 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
| US5935946 | GILEAD | Nucleotide analog composition and synthesis method |
Jul, 2017
(6 years ago) | |
| US6703396 | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5814639 (Pediatric) | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(8 years ago) | |
| US6043230 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
|
US5914331 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(6 years ago) | |
|
US5935946 (Pediatric) | GILEAD | Nucleotide analog composition and synthesis method |
Jan, 2018
(6 years ago) | |
|
US5922695 (Pediatric) | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(6 years ago) | |
|
US5977089 (Pediatric) | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
|
US6043230 (Pediatric) | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
| US6642245 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
|
US6642245 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(2 years ago) | |
|
US6703396 (Pediatric) | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(2 years ago) | |
| US9744181 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
| US8592397 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
| US8716264 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
| US9457036 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
|
US8716264 (Pediatric) | GILEAD | Compositions and methods for combination antiviral therapy |
Jul, 2024
(2 months from now) | |
Truvada is owned by Gilead.
Truvada contains Emtricitabine; Tenofovir Disoproxil Fumarate.
Truvada has a total of 21 drug patents out of which 20 drug patents have expired.
Expired drug patents of Truvada are:
- US5814639*PED
- US6043230
- US5914331*PED
- US5935946*PED
- US5922695*PED
- US5977089*PED
- US6043230*PED
- US6642245
- US6642245*PED
- US6703396*PED
- US9744181
- US8592397
- US8716264
- US9457036
- US5814639
- US5914331
- US5922695
- US5977089
- US5935946
- US6703396
Truvada was authorised for market use on 10 March, 2016.
Truvada is available in tablet;oral dosage forms.
Truvada can be used as prophylaxis of hiv-1 infection, treatment of hiv, treatment of hiv-1 infection in pediatric patients 12 years of age and older, method of treatment of adults infected with hiv-1, treatment of hiv infection.
The generics of Truvada are possible to be released after 13 July, 2024.
Drugs and Companies using EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: Prophylaxis of hiv-1 infection; Method of treatment of adults infected with hiv-1; Treatment of hiv infection; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment o...
Dosage: TABLET;ORAL
TRUVADA family patents
